Veeva Systems: Industry Survey Reveals Clinical Data Management Delays Are Slowing Trial Completion
One of the largest, most in-depth surveys of clinical data management professionals shows that the time it takes companies to design and release clinical study databases is having a negative impact on conducting and completing trials.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005594/en/
Types of data companies manage in their primary EDC vs. volume of data (Graphic: Business Wire)
According to the 2017 eClinical Landscape Study from Tufts Center for the Study of Drug Development, it takes companies an average of 68 days to build and release a clinical study database. Delays in releasing the study database are associated with an increase of nearly a month downstream for other data management processes such as patient data entry and time to lock the database at the end of the study. Respondents that deliver the database after first patient, first visit (FPFV), take nearly twice as long to enter patient data throughout the study and about 75% longer to lock the study database when compared to those that deliver the final database before FPFV.
“The study results indicate that companies face a growing number of challenges in building and managing clinical study databases,” said Ken Getz, research associate professor and director at the Tufts Center for the Study of Drug Development. “The results also show that the release of the clinical study database after sites have begun enrollment is associated with longer downstream cycle times at the investigative site and at study close out.”
Electronic Data Capture (EDC) Providers and System Use
EDC is the most widely adopted clinical application, used by all respondents (100%), followed by randomization and trial supply management (77%), electronic master file (70%), and safety (70%) systems. A majority (58%) of respondents use either Medidata Rave or Oracle Inform as their primary EDC system.
When asked about the type of data managed in their EDC, all (100%) CROs and sponsors cite electronic case report form (eCRF) data, followed by local lab and quality of life data (60% each). However, respondents say eCRF data is the highest volume of data they manage in their EDC system (at an average of 78% of the total data managed). The next highest data volumes reported are central lab data and local lab data at 5% each. Remaining data types reported are each 4% or less. This demonstrates the need for processes and systems to support the industry’s vision to have complete study data in their EDC.
More than three-quarters (77%) say they have issues loading data into their EDC application and most (66%) say EDC system or integration issues are the primary reasons they are unable to load study data.
Impact of Database Build Delays on Trial Cycle Times
The survey finds several common causes for clinical database build delays. Protocol changes is cited most by 45% of respondents, underscoring the challenge data management professionals have in dealing with changes as they are finalizing the clinical trial database for the start of the trial. This highlights the need to optimize the database design process with standards and systems that support more flexible design and rapid development.
Initial database delays also have significant downstream impacts on the time it takes sites to enter patient data in the EDC throughout the trial, as well as the final lock of the database once the study is complete. It takes on average five days from patient visit to when the data is entered into the EDC for companies that release the database before FPFV. When the database is released after FPFV, data entry time doubles to 10 days.
The impact of database build delays is even greater by the time companies get to database lock. Those who always release the database before FPFV get to database lock in an average of 31 days. Those who never release the database before FPFV take more than three weeks longer (54 days) to lock the database.
Sponsors take roughly 40% longer than CROs to build the database (73 vs. 53 days) and to get to database lock (39 vs. 28 days). Also, those using the two leading EDC systems report roughly 20% longer data cycle times (123 days) than those using other EDC systems (99 days), which includes time for database build (75 vs. 60 days), patient data entry (9 vs. 7 days), and database lock (39 vs. 32 days).
“Database build processes have remained largely unchanged over the past 10 years, and the process will only get more complicated as CROs and sponsors manage an increasing variety of clinical trial data,” said Richard Young, vice president of Veeva Vault EDC. “Organizations compensate for technology limitations by reducing the volume of data they input. Our focus should be on improving EDC systems so sponsors and CROs are no longer limited, and instead can run the trial they want.”
The 2017 eClinical Landscape Study: Assessing Data Management Practices, Performance, and Challenges from Tufts Center for the Study of Drug Development, sponsored by Veeva Systems (NYSE: VEEV), reviews the state of data management in life sciences with an in-depth look at the insights and opinions of clinical data management professionals at more than 250 companies, including sponsors and CROs, with an average of 17 years of experience in clinical data management. Download the report at veeva.com/eu/EDCSurvey.
About the Tufts Center for the Study of Drug Development
The Tufts Center for the Study of Drug Development at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues. For more information, visit csdd.tufts.edu.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
2017 eClinical Landscape Study:
Assessing Data Management Practices, Performance, and Challenges
The 2017 eClinical Landscape Study examines the state of clinical data management in the life sciences industry. The goal of the research is to understand current clinical data management practices and assess the performance and challenges of electronic data capture (EDC) systems.
One of the largest, most in-depth clinical data management studies to date, this research captures the insights and opinions of 250 clinical data management professionals, including sponsors and CROs with an average of 17 years of clinical data management experience.
Clinical Systems and EDC Data Landscape
- EDC applications are the most prevalent clinical applications, used by all (100%) respondents, followed by randomization and trial supply management (77%), safety/pharmacovigilance (70%), electronic trial master file (eTMF) (70%), and clinical trial management (CTMS) (61%) systems.
- A majority (58%) of respondents use Medidata Rave or Oracle Inform as their primary EDC application. No other application was used by more than 6% of organizations.
- While all respondents use an EDC system, roughly one-third (32%) use paper case report forms (CRFs), indicating these organizations still rely on manual processes to manage data during their clinical trials.
- Organizations say they manage a wide range of data types in their primary EDC system including eCRF (100%), local lab (60%), quality of life (60%), central lab (57%), and ePRO (34%) data. Only 10% of companies have genomic data or mobile health data in their EDC.
- While companies have variety of data types in their EDC, respondents say the largest proportion of the data in their EDC system is eCRF data (estimated at 78% of total data managed). All other data types were each estimated at 5% or less of the total volume of data in the EDC, including local lab data (5%), central lab data (5%), quality of life data (4%), and ePRO data (3%). Genomic data and mobile health data make up the smallest portion of data in EDC systems at 0.4% and 0.3% respectively.
Clinical Data Management Cycle Times
- On average, it takes 68 days to build and release a study database, 8 days from patient visit to enter data in the EDC system throughout the study, and 36 days from the study’s last patient visit to database lock.
Sponsors, as well as those using the two most prevalent EDC
applications (Medidata Rave and Oracle Inform), report longer times to
build and release the study database and to lock the database after
last patient, last visit.
Average number of days to build and release the database:
- 73 days for sponsors vs. 53 days for CROs
- 75 days for those using the two most widely used EDC systems vs. 60 days for those using other EDC systems
Average number of days to lock the study database:
- 39 days for sponsors vs. 28 days for CROs
- 39 days for those using the two most widely used EDC systems vs. 32 days for those using other EDC systems
- Average number of days to build and release the database:
Clinical Study Database Build Times and the Impact on Clinical Trial Cycle Times
The up-front time it takes to build and release the clinical database
has potentially significant impacts on downstream processes, including
time to enter patient data in the EDC throughout the study and time to
final database lock after last patient, last visit.
- It takes on average five days from patient visit to when the data is entered into the EDC for companies that release the database before FPFV, and database lock time is 31 days.
- It takes on average 10 days from patient visit to when the data is entered into the EDC for companies that release the database after FPFV, and database lock time is 54 days.
- Nearly one-third (32%) of sponsors “often” or “always” release their EDC after FPFV has occurred, compared to 20% of CROs.
- One-third (36%) of those using the two most prevalent EDC applications “often” or “always” release their EDC after FPFV has occurred, compared to 22% of those using other EDC applications.
Top Causes for Database Build Delays and Data Loading Challenges
- The most common cause for database build delays is protocol changes (45%), followed by user acceptance testing (17%), and database design functionality (15%).
- Database build delays due to protocol changes are higher among CROs (52%) than sponsors (44%). Whereas database build delays due to design functionality are lower among CROs (7%) than sponsors (18%).
- Database build delays due to database design functionality is associated with significantly longer time to lock the database after last, patient last visit (50 days vs. the 36-day average).
- Three-quarters of respondents (77%) have issues that prevent them from loading data into their primary EDC system. Most (66%) cite EDC system issues or integration issues as the top challenges that prevent them from loading data.
For Veeva Systems Inc.
Sue Glanville / Cate Bonthuys
email@example.com / firstname.lastname@example.org
+44 (0) 7715 817589 / +44 (0) 7746 546773
Tufts Center for the Study of Drug Development
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IFF Declares Dividend for Fourth Quarter 201713.12.2017 21:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that its Board of Directors has declared a regular quarterly cash dividend of $0.69 per share of the Company’s common stock, payable on January 8, 2018 to shareholders of record as of December 29, 2017. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take a
Limelight Networks Enhances DDoS Security Services with Faster Mitigation of Malicious Website Attacks13.12.2017 19:18 | Pressemelding
Limelight Networks, Inc. (Nasdaq: LLNW), a global leader in digital content delivery, today introduced new capabilities to its DDoS Attack Interceptor Service that provide high-capacity on-network scrubbing and a scalable range of protection measures for web infrastructure, with the ability to easily increase protection as security requirements change. Protecting websites from online attacks and cyber threats is one of the most pressing security challenges today. For example, data from Limelight’s State of Cybersecurity Report: SE Asia shows consumers are very concerned about the security of ecommerce sites, with 72 percent saying they have a negative opinion of a brand after hearing that it has suffered a cyberattack. In addition, 51 percent of online websites feel they are vulnerable to attacks that could have significant financial and b
Interactive Brokers Now Allowing Short Positions in Bitcoin Futures13.12.2017 17:15 | Pressemelding
Interactive Brokers Group, Inc. (NASDAQ GS: IBKR), a global electronic brokerage firm, will now accept orders for short sales of Cboe Futures Exchange (CFE) Bitcoin futures that began trading on the IBKR platform on Sunday, December 10, 2017. Interactive Brokers requires margin of $40,000 per contract for short sales in CFE Bitcoin futures. Margin on long positions of CFE Bitcoin futures is currently $9,000. “The introduction of short sales was necessitated by the large premium of the January futures contract over the price at which Bitcoin trades on the physical venues,” said Interactive Brokers founder, Chairman and CEO Thomas Peterffy. Interactive Brokers requires customers who wish to trade Bitcoin futures to execute a special agreement acknowledging the risk inherent in the contract. Current and new clients can learn more about trading Bitcoin futures with IBKR a
Sunny Optics Officially Licenses ImmerVision Panomorph Lens Technology for Global Production13.12.2017 12:47 | Pressemelding
ImmerVision, developer of exclusive and patented panomorph wide-angle imaging technology, is proud to announce that Sunny Optics (Zhongshan) Co., a subsidiary of Sunny Optical Technology (Group) Co. Ltd., a leading manufacturer of integrated optical components and products, has licensed panomorph lens technology for global production, and will deliver its first small form-factor panomorph high-resolution super-wide-angle lenses for smartphones and mobile devices in Q1 2018. Panomorph lens technology combines state-of-the-art optical design and advanced, optimized algorithms, including low-power dewarping, to produce high-resolution super-wide-angle images without distortion, even in low light conditions. Sunny Optical is the largest Chinese lens supplier for the most popular smartphone brands and OEM applications such as sports cameras, surveillance, 360 image capture, autom
Synacor Launches Enhancements to Zimbra Communications and Collaboration Suite13.12.2017 12:30 | Pressemelding
Synacor Inc. (NASDAQ:SYNC) today announced the commercial launch of Zimbra 8.8. The easy-to-use collaboration platform comes with new user experience features such as Zimbra Drive for enterprise-level file sync and sharing and Zimbra Chat. The Network Edition features tech stack enhancements including real-time backup, ActiveSync across mobile and desktop, hierarchical storage management (HSM) that enables customers to move archival data to less expensive storage solutions, and improved delegated admin functionality. “Zimbra 8.8 is an exciting update for end users and technical decision makers,” said Marcus Teo, Vice President, Enterprise Sales & Marketing, Synacor. “Customers look to Zimbra for security, privacy and transparency through open code, extensibility, accessibility on multiple devices and deployment flexibility. This update builds on these tenets and incorporates enhancemen
GSMA Urges Members of the World Trade Organization to Prioritise and Accelerate Investment in Digital Future13.12.2017 12:00 | Pressemelding
On the occasion of the 11th World Trade Organization (WTO) Ministerial Conference, GSMA Director General Mats Granryd called on government leaders to reform their regulatory frameworks in order to encourage a new wave of innovation and investment in digital infrastructure and services. Currently, 108 of the WTO's 164 members have made commitments to facilitate trade in telecoms services, such as the right to establish new telecoms companies, make foreign direct investment in existing companies and enable the cross-border transmission of telecoms services. “Today, more than 5.1 billion people – about two-thirds of the world’s population – subscribe to mobile services. With this broad reach, the mobile industry is a major driver in the global economy, expected to employ nearly 31 million people worldwide and contribute $4.2 trillion in economic value (4.9 per cent of GDP) in 2020,” said
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom